In a mouse model of primary hyperoxaluria type 1, a single intravenous injection of AAV8 carrying the paired CRISPR-Cas9 nickases system targeting the Hao1 gene in hepatocytes resulted in efficient and safe gene disruption and a significant therapeutic effect. Here, HAO1 is linked to primary hyperoxaluria type 1.